Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors

NCT03496519 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT03496519
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03496519 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Assessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid Tumors
Lead sponsor
University of Colorado, Denver
Phase
Phase 1
Overall status
Withdrawn
Start date
October 1, 2018
Completion date
October 31, 2021
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumor, adult